SNDX-5613
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for SNDX-5613, covering 2026-02-17 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene [Phase 1]